ReviewDrug discovery today2018
The role of fMRI in drug development.
Review in Drug discovery today, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity: A Systematic Review.JAMA psychiatry · 2024Pooled it
- Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.Neuroscience and biobehavioral reviews · 2023Pooled it
- fMRI as an outcome measure in clinical trials: A systematic review in clinicaltrials.gov.Brain and behavior · 2021Pooled it
- Effects of Ketamine and Midazolam on Simultaneous EEG/fMRI Data During Working Memory Processes.Brain topography · 2021Trial
- Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial.JAMA psychiatry · 2020Trial
- Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.The international journal of neuropsychopharmacology · 2019Trial
- Opioid-specific brain connectivity dynamics distinguish analgesia from secondary effects: Studies in male mice.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.Journal of psychopharmacology (Oxford, England) · 2026Article
- Article
- Re-evaluating our focus in addiction: emotional dysregulation is a critical driver of relapse to drug use.Translational psychiatry · 2024Review
- Advancing Pain Understanding and Drug Discovery: Insights from Preclinical Models and Recent Research Findings.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Neuroimaging Biomarkers in Addiction.medRxiv : the preprint server for health sciences · 2024Article
- Can we achieve pain stratification in musculoskeletal conditions? Implications for clinical practice.Frontiers in pain research (Lausanne, Switzerland) · 2024Review
- Pharmacological manipulation of neurotransmitter activity induces disparate effects on cerebral blood flow and resting-state fluctuations.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Closing the loop between brain and electrical stimulation: towards precision neuromodulation treatments.Translational psychiatry · 2023Review
- The Role of fMRI in Drug Development: An Update.Advances in neurobiology · 2023Article
- Experimental Medicine Approaches in Early-Phase CNS Drug Development.Advances in neurobiology · 2023Article
- Magnetic resonance imaging and ultrasound elastography in the context of preclinical pharmacological research: significance for the 3R principles.Frontiers in pharmacology · 2023Review
- Review: The use of functional magnetic resonance imaging (fMRI) in clinical trials and experimental research studies for depression.Frontiers in neuroimaging · 2023Review
- A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus.Nature protocols · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Functional magnetic resonance imaging (fMRI) has been known for over a decade to have the potential to greatly enhance the process of developing novel therapeutic drugs for prevalent health conditions. However, the use of fMRI in drug development continues to be relatively limited because of a variety of technical, biological, and strategic barriers that continue to limit progress. Here, we briefly review the roles that fMRI can have in the drug development process and the requirements it must meet to be useful in this setting. We then provide an update on our current understanding of the strengths and limitations of fMRI as a tool for drug developers and recommend activities to enhance its utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.